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In our recent review and meta-analyses of reports of long-term 
trials of treatments for major depressive disorder patients, we 
noted that remarkably little potentially relevant and interesting 
clinical information was included in most reports (Sim et al., 
2015). This limitation seemed particularly remarkable in long-
term studies carried out at great effort and expense. In general, 
reports of clinical trials in various disorders appear to focus 
rather narrowly on outcomes for which the trials were designed, 
usually rates of relapse or recurrence of a particular illness 
(Baldessarini, 2013).
In an effort to evaluate this impression more closely, we 
re-reviewed the reports cited in our review (Sim et al., 2015), 
focusing specifically on any indications of suicidal behaviors, 
which are of particular interest with major mood disorder 
patients. We recorded any comment or data pertaining to sui-
cidal events, including completed suicides, attempts or self-
injuries, or suicidal ideation typically significant enough as 
to require removal from the trial. Exposure times include not 
only the long-term phases of the trials but also lead-in weeks 
with placebo treatment as well as initial open-label phases of 
antidepressant treatment prior to randomization to continue 
active treatment or discontinue to placebo, with categorization 
based on the treatment assigned during the long-term phases 
of trials.
Very few reports included information concerning suicidal risks, 
even broadly defined. In all, we found 12 such publications among 
85 (14.1%) reviewed reports. Reports with any information about 
suicidal events included 6 placebo-controlled continuation trials for 
up to 1 year, 6 antidepressant trials lasting more than 12 months, 
and no trial of a psychosocial treatment (Sim et al., 2015) (Table 1). 
Most of the 12 reports provided only brief comments as to whether 
or not suicides or attempts occurred in active treatment or control 
arms of the trials, most of which had attempted to exclude cur-
rently suicidal subjects. The very low yield of 14.1% of trials report-
ing any information about suicidal events during the trials was 
surprising.
It is also noteworthy that the average rates of suicide 
attempts and suicides were very high despite efforts to exclude 
currently suicidal patients. The risk of suicide averaged 1.08%/
year, and of attempts, 2.24%/year, across treatment arms of 
trials. In addition, there was an ominously low apparent ratio 
of attempts/suicides of 2.07, compared with >30 in the gen-
eral population (Kessler et  al., 2005; Tondo et  al., 2007). The 
observed rates of attempts and suicides are far higher than in 
the general population and even higher than those reported in 
clinical samples of outpatients diagnosed with major depres-
sive disorder, which average approximately 0.045%/year for 
suicide and 0.480%/year for attempts (Bostwick and Pankratz, 
2000; Tondo et al., 2007). Such high levels of suicidal risk may 
reflect the difficulty of excluding potentially suicidal subjects 
from trials and the fact that trial entry required being acutely 
depressed in order to study treatment effects (Sim et al., 2015). 
Nevertheless, if the findings are valid and representative, they 
underscore the importance of considering suicidal risks in 
such trials.
Even more remarkable were indications that the overall risk 
of suicidal events was significantly greater in trial arms involv-
ing active, antidepressant treatment vs placebo controls when 
findings were pooled across all 12 trials and in 9/12 of the tri-
als (Table 1). However, since none of the trials was specifically 
designed to address suicidal risk and the trials yielding data 
on suicidal risks were few, the summarized observations may 
merely represent chance findings, with risk of selective overre-
porting of high rates. Alternatively, they parallel the unresolved 
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relationships of antidepressant exposure to suicidal risks 
(Baldessarini et al., 2007; Stone et al., 2009; Nischal et al., 2012), 
and surely they warrant further study.
The present findings strongly encourage the recommenda-
tion that important outcomes of clinical and research signifi-
cance more routinely be included in reports of treatment trials 
for psychiatric disorders, especially trials involving long-term 
observations under controlled conditions, if only to limit biased, 
selective reporting of unrepresentative findings. Suicidal risk 
among mood disorder patients is only one example. The pro-
vocative and unexpected finding of very high reported, pooled 
rates of suicide and attempts and greater observed suicidal 
risks with antidepressant treatment than with placebo indicate 
the need to pursue these unexpected findings. In general, we 
support the research practice of including information about 
suicidal risk as well as other clinical measures of interest, rou-
tinely, in the design, conduct, and reporting of psychiatric treat-
ment trials.
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Table 1. Suicidal Events in Long-Term, Controlled Treatment Trials for Major Depressive Disorder
Study Treatment
Exposure
(years)
Subjects
Suicidal Events:  
Ideation/Attempts/ 
Suicides
Incidence (events/ 
100 person-years)
Treatment Placebo Treatment Placebo Treatment Placebo
Doogan and Caillard 1992 Sertraline 1.17 185 110 0/3/0 0/1/0 3/216.5 (1.39) 1/128.7 (0.78)
Montgomery and Dunbar 1993 Paroxetine 1.15 68 67 0/0/1 0/0/0 1/78.2 (1.28) 0/77.0 (0.00)
Versiani et al., 1999 Reboxetine 1.08 145 141 0/0/2 0/0/0 2/156.6 (1.28) 0/152.3 (0.00)
Rouillon et al., 2000 Milnacipran 1.48 104 110 0/8/2 0/5/1 10/153.9 (6.50) 6/162.8 (3.69)
Schmidt et al., 2000 Fluoxetine 0.73 379 122 1/0/0 1/0/0 1/276.7 (0.36) 1/89.7 (1.12)
Thase et al., 2001 Mirtazapine 0.98 76 80 0/2/0 0/0/0 2/74.5 (2.68) 0/78.4 (0.00)
Kornstein et al., 2006 Escitalopram 1.46 73 66 0/0/0 0/1/0 0/106.6 (0.00) 1/96.4 (1.04)
Keller et al., 2007 Venlafaxine 2.65 43 86 0/0/0 1/0/0 0/114.0 (0.00) 1/227.9 (0.44)
Kocsis et al., 2007 Venlafaxine 1.65 164 172 1/0/0 1/0/0 1/270.6 (0.37) 1/283.8 (0.35)
Kelin et al., 2010 Duloxetine 1.62 64 60 0/0/0 0/0/0 0/103.7 (0.00) 0/97.2 (0.00)
Liebowitz et al., 2010 Quetiapine 1.48 391 385 9/0/0 1/0/0 9/578.7 (1.56) 1/569.8 (0.18)
Rosenthal et al., 2013 Desvenlafaxine 0.92 272 276 5/5/0 0/0/0 10/2720 (0.37) 0/253.9 (0.00)
Totals/Means
[95%CI]
(12 trials) 1.36
[1.05–1.68]
1964 1675 16/18/5
(39)
4/7/1
(12)
39/2671 (1.46)
[1.03–2.00]
12/2278 (0.53)
[0.27–0.92]
The observed incidence rate ratio (IRR for suicidal events/100 person-years) indicates 2.77-fold [CI: 1.42–5.82] greater with antidepressants vs placebo (exact P = .0005). 
Observed incidence (%/y) with antidepressant treatment vs placebo (based on N and time from reporting studies only) was: ideation (1.11 vs 0.32), attempts (2.48 vs 
1.79), suicides (1.28 vs 0.61), and suicidal acts (attempts + suicides: 2.03 vs 1.44; corresponding IRR [with 95%CI] were: ideation (3.45 [1.11–14.2]; P = .009), attempts (1.39 
[0.55–3.94]; P = .24), suicides (2.08 [0.23–98.2], P = .28), and suicidal acts (1.40 [0.61–3.63], P = .21). References to trials cited are provided in Sim et al. (2015).
